Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPRESSION: Intensive BP and Cholesterol Management in Elderly Chinese
NCT04111419Phase 4
Key facts
- Status
- Active, not recruiting
- Start
- Jul 2020
- Primary completion
- Sep 2026
- Countries
- 1
- Sponsor
- Shanghai Jiao Tong University School of Medicine
- Modality
- Small Molecules
- Conditions
- hypertension (HTN)hypercholesterolemia
01
Overview
Phase 4, randomised, open-label trial of allisartan isoproxil and atorvastatin in hypertension (HTN) and hypercholesterolemia (4 arms), sponsored by Shanghai Jiao Tong University School of Medicine. Primary endpoint: Combined cardiovascular end-point events at 3 years. Started Jul 2020; status: active, not recruiting.
02
Design
4 arms- Study design
- RandomizedOpen-label
Intensive BP & Cholesterol
Amlodipine/Atorvastatin 5/20mg + Allisartan 240mg
Intensive BP & Routine Cholesterol
Amlodipine/Atorvastatin 5/10mg + Allisartan 240mg
Routine BP & Intensive Cholesterol
Amlodipine/Atorvastatin 5/20mg
Routine BP & Cholesterol
Amlodipine/Atorvastatin 5/10mg
03
Who it enrols
Elderly Chinese patients (>=65 years) with hypertension and atrial fibrillation, SBP 140-179 mmHg or DBP 90-109 mmHg, not on >1 antihypertensive drug.
04
Endpoints
Primary
Combined cardiovascular end-point events
Beyond the preview
Go deeper on NCT04111419.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04111419.